Daily Hong Kong Stock Market News Briefing (December 18, Wednesday)
Individual Stock News
-
CHINAHONGQIAO (01378.HK): Benefiting from favorable factors such as rising aluminum product prices, the group's net profit for the year ending December 31, 2024, is expected to increase by about 95% compared to the same period in 2023.
-
CEB BANK (06818.HK): Nominated Huang Zhenzhong as a candidate for independent non-executive director of the ninth board of directors.
-
CICC (03908.HK) completed the issuance of CNY 3.5 billion perpetual subordinated bonds at a price of CNY 100 per bond, with a coupon rate of 2.15%.
-
R&F Properties (02777.HK): The hearing regarding R&F Hong Kong and Zhaoxi has been postponed to March 31, 2025.
-
HANSOH PHARMA (03692.HK): The injectable HS-20110 has received the drug clinical trial approval notice issued by the National Medical Products Administration.
-
Ping An Asset Management increased its holdings in Industrial and Commercial Bank of China (01398.HK) by 28.664 million shares at a price of HKD 4.7987 per share, totaling approximately HKD 138 million.
-
China Xuyang Group (01907.HK): Shenzhen Capital Group plans to inject an additional CNY 800 million into Cangzhou Xuyang Chemical.
-
Kelun-Biotech (06990.HK) subscribed to a total of CNY 300 million in structured deposits with Industrial Bank, with the total unpaid principal amount of financial products at Industrial Bank being CNY 420 million.
-
Guolian Securities (01456.HK) has received approval from the merger and reorganization committee for the acquisition of 99.26% of Minsheng Securities.
-
China Coal Energy (01898.HK): The sales volume of commercial coal in the first 11 months was 256 million tons, a year-on-year decrease of 1.9%; sales in November were 25.8 million tons, a year-on-year increase of 11.4%